1. Aligos presented positive data on ALG-055009 at HEP-DART 2025. 2. New data reveal ALG-055009 enhances weight loss with incretin receptor agonists. 3. Combination therapies showed significant fat loss without affecting lean mass. 4. Potential for ALG-055009 as a key player in cardiometabolic treatments. 5. Aligos' HBV therapies demonstrate promise for chronic infection management.
FAQ
Why Bullish?
The positive data on ALG-055009 suggests its commercial viability and can attract investor interest. Historical examples indicate that successful clinical results often lead to stock price increases.
How important is it?
The article highlights significant advancements in Aligos' clinical programs, enhancing ALGS's attractiveness to investors.
Why Long Term?
The long-term impact is based on potential future commercialization of ALG-055009 and ongoing advancements in the company's pipeline.
Aligos Therapeutics Unveils Promising Data at HEP-DART 2025
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, has announced significant findings derived from four presentations, including two oral presentations, during the HEP-DART 2025 Meeting held from December 7 to 11, 2025, in Honolulu, Hawaii. This event showcased innovative research on therapies for liver and viral diseases, emphasizing Aligos' commitment to improving patient outcomes.
Phase 1 Study of Pevifoscorvir Sodium for Chronic HBV
The presentations featured vital data concerning pevifoscorvir sodium, a potent cyclophilin A modulator (CAM-E) under development for chronic hepatitis B virus (HBV) infection. The comprehensive 96-week and follow-up results from the Phase 1 monotherapy study (NCT04536337) indicate a strong potential for this therapy to emerge as a first-line treatment for **chronic suppression** of HBV. These findings reflect Aligos' ongoing dedication to addressing unmet medical needs in this arena.
Innovative Nonclinical Results for ALG-055009
Aligos also presented groundbreaking nonclinical data on ALG-055009, a thyroid hormone receptor beta (THR-β) agonist designed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). This research focused on diet-induced obese (DIO) mice and highlighted the synergistic effects observed when ALG-055009 was administered alongside incretin receptor agonists (RAs) such as semaglutide (SEMA) and tirzepatide (TIRZEP).
- SEMA monotherapy led to a maximum weight loss of 23.9 ±2.6%.
- Combining SEMA with ALG-055009 resulted in an overall weight loss of 33%.
- TIRZEP showed weight loss of 27.1 ±2.7% and 34.4 ±1.6% for low and high doses, respectively.
- Combination therapies produced weight loss enhancements of up to 40%.
The data indicates that the additional weight loss in combination therapies was primarily attributed to fat mass reduction without significant changes in lean mass or food consumption, highlighting the potential of ALG-055009 when paired with these incretin receptor agonists.
Insights from Leadership
Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics, expressed, “We are pleased to present these data at the 30th anniversary meeting of HEP-DART. The results affirm our enthusiasm for the potential of pevifoscorvir sodium in treating chronic HBV infections. We are equally excited to share the nonclinical data for ALG-055009, which demonstrated a remarkable synergistic effect with incretin receptor agonists.” He emphasized the importance of ALG-055009 in future combination therapies within the cardiometabolic space.
Presentation Details and Future Directions
The details of the highlighted presentations are as follows:
- Pevifoscorvir Sodium: Oral Presentation on antiviral effects in treatment-naïve patients. Presented by Lawrence Blatt, PhD, MBA on December 9, 2025.
- ALG-055009: Oral & Poster Presentation demonstrating synergistic fat mass loss in DIO mice when combined with incretin receptor agonists. Presented by Xuan (Susan) Luong, PhD.
- Preclinical ASO Strategies: Additional poster presentations on HBV and HDV by Lawrence Blatt and David B. Smith, PhD.
For deeper insights, the presentations will be accessible on the Aligos website.
About Aligos Therapeutics
Aligos Therapeutics, Inc. (NASDAQ: ALGS) focuses on developing best-in-class therapies for liver and viral diseases. By leveraging robust R&D capabilities, Aligos addresses critical health needs, including chronic HBV infections, obesity, and MASH. More information about Aligos can be found at www.aligos.com or by following the company on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements, which involve inherent risks and uncertainties that may cause actual results to differ from those projected. Such statements pertain to Aligos’ research developments and do not guarantee future performance or achievements.